预约演示
更新于：2025-02-17
18F-Fluoromisonidazole
更新于：2025-02-17
概要
基本信息
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H8FN3O3 |
InChIKeyHIIJZYSUEJYLMX-JZRMKITLSA-N |
CAS号104613-87-8 |
关联
36
项与 18F-Fluoromisonidazole 相关的临床试验NCT04332588
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT05996432
Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
NCT04846309
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
100 项与 18F-Fluoromisonidazole 相关的临床结果
登录后查看更多信息
100 项与 18F-Fluoromisonidazole 相关的转化医学
登录后查看更多信息
100 项与 18F-Fluoromisonidazole 相关的专利（医药）
登录后查看更多信息
397
项与 18F-Fluoromisonidazole 相关的文献（医药）2025-01-01Methods in Cell Biology
Quantitative pre-clinical imaging of hypoxia and vascularity using MRI and PET
Article
作者: Jirik, Radovan ; Boudissa, Selma ; Rolfsnes, Hans Olav ; Pacheco-Torres, Jesus ; Kanli, Georgia ; Janji, Bassam ; Adamsen, Tom ; Espedal, Heidi ; Thorsen, Frits ; Keunen, Olivier
During hypoxia, tissues are subjected to an inadequate oxygen supply, disrupting the balance needed to maintain normal function. This deficiency can occur due to reduced oxygen delivery caused by impaired blood flow or a decline in the blood's ability to carry oxygen. In tumors, hypoxia and vascularization play crucial roles, shaping their microenvironments and influencing cancer progression, response to treatment and metastatic potential. This chapter provides guidance on the use of non-invasive imaging methods including Positron Emission Tomography and Magnetic Resonance Imaging to study tumor oxygenation in pre-clinical settings. These imaging techniques offer valuable insights into tumor vascularity and oxygen levels, aiding in understanding tumor behavior and treatment effects. For example, PET imaging uses tracers such as [18F]-fluoromisonidazole (FMISO) to visualize hypoxic areas within tumors, while MRI complements this with anatomical and functional images. Although directly assessing tumor hypoxia with MRI remains challenging, techniques like Blood Oxygen Level Dependent (BOLD) and Dynamic Contrast-Enhanced MRI (DCE-MRI) provide valuable information. BOLD can track changes in oxygen levels during oxygen challenges, while DCE-MRI offers real-time access to perfusion and vessel permeability data. Integrating data from these imaging modalities can help assess oxygen supply, refine treatment strategies, enhance therapeutic effectiveness, and ultimately improve patient outcomes.
2024-11-01JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
Evaluation of an automated synthesis method for [18F]Fluoromisonidazole using a Scintomics GRP® module
作者: Le Roux, Jannie ; Rubow, Sietske ; Oliver, Jayed
Abstract:
There is limited information on utilizing commercially supplied [18F]Fluoride from an off-site cyclotron for the synthesis of radiopharmaceuticals. This study explored the production of the PET hypoxia marker [18F]FMISO, using the Scintomics® GRP module and distantly produced [18F]Fluoride, which lacks published data. A radiochemical yield of 27.4 ± 3.6% (n = 5) and high radiochemical purity were achieved in synthesis time of 48 min. The [18F]FMISO met all Ph. Eur. standards, demonstrating the consistency and reliability of the module in generating a clinical-grade radiopharmaceutical using off-site produced [18F]Fluoride, but available patient doses were severely limited.
2024-11-01Biomedical Physics & Engineering Express
Mathematical modeling of 18F-Fluoromisonidazole (18F-FMISO) radiopharmaceutical transport in vascularized solid tumors
Article
作者: Soltani, M ; Abazari, Mohammad Amin ; Kashkooli, Farshad Moradi ; Rahmim, Arman ; Eydi, Faezeh
Abstract:
18F-Fluoromisonidazole (18F-FMISO) is a highly promising positron emission tomography radiopharmaceutical for identifying hypoxic regions in solid tumors. This research employs spatiotemporal multi-scale mathematical modeling to explore how different levels of angiogenesis influence the transport of radiopharmaceuticals within tumors. In this study, two tumor geometries with heterogeneous and uniform distributions of capillary networks were employed to incorporate varying degrees of microvascular density. The synthetic image of the heterogeneous and vascularized tumor was generated by simulating the angiogenesis process. The proposed multi-scale spatiotemporal model accounts for intricate physiological and biochemical factors within the tumor microenvironment, such as the transvascular transport of the radiopharmaceutical agent, its movement into the interstitial space by diffusion and convection mechanisms, and ultimately its uptake by tumor cells. Results showed that both quantitative and semi-quantitative metrics of 18F-FMISO uptake differ spatially and temporally at different stages during tumor growth. The presence of a high microvascular density in uniformly vascularized tumor increases cellular uptake, as it allows for more efficient release and rapid distribution of radiopharmaceutical molecules. This results in enhanced uptake compared to the heterogeneous vascularized tumor. In both heterogeneous and uniform distribution of microvessels in tumors, the diffusion transport mechanism has a more pronounced than convection. The findings of this study shed light on the transport phenomena behind 18F-FMISO radiopharmaceutical distribution and its delivery in the tumor microenvironment, aiding oncologists in their routine decision-making processes.
1
项与 18F-Fluoromisonidazole 相关的新闻（医药）2024-12-27
100 项与 18F-Fluoromisonidazole 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 18F-Fluoromisonidazole | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝细胞癌 | 临床2期 | - | - | |
| 肝细胞癌 | 临床2期 | - | - | |
| 高级别胶质瘤 | 临床1期 | 美国 | 2021-02-01 | |
| 缺氧 | 临床1期 | 美国 | 2021-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (FMISO PET positive for tumor hypoxia) | 製餘選築範築繭壓鬱蓋(糧齋築餘鏇簾鏇鹹選築) = 壓鑰衊膚選願醖艱膚製 糧夢艱積築淵齋齋鬱遞 (淵廠蓋鑰鏇鏇築醖壓鬱 ) 更多 | - | 2024-10-01 | ||
(FMISO PET negative for tumor hypoxia) | - | ||||||
N/A | IDH-mutated | 16 | [18F]-Fluoromisonidazole PET | 壓蓋廠窪遞鑰膚網膚窪(願築簾選鬱構鹹獵齋選) = 齋衊襯構繭簾糧壓淵遞 夢艱壓網醖鏇繭獵衊遞 (築繭憲築鏇築鹽鬱襯顧, 0.0016) | 积极 | 2023-11-10 | |
临床2期 | 53 | Standard radiotherapy (ST) | 夢構淵醖憲範顧製醖壓(繭齋壓衊齋鹽艱願網夢) = 窪衊繭艱壓齋鹹遞顧構 構膚簾糧窪構夢製簾鑰 (製獵繭淵鑰獵鹽構繭遞 ) | - | 2022-06-01 | ||
Dose escalation (DE) | 夢構淵醖憲範顧製醖壓(繭齋壓衊齋鹽艱願網夢) = 築襯廠鑰積餘簾醖鏇廠 構膚簾糧窪構夢製簾鑰 (製獵繭淵鑰獵鹽構繭遞 ) | ||||||
临床2期 | 3 | 壓鹽選鹽廠艱鬱壓鬱製(觸簾醖窪夢醖簾餘網衊) = 獵淵築廠糧憲淵鬱鏇衊 鹹願餘遞鹹願窪襯網範 (醖鹽艱鹽憲襯膚製鑰糧, 繭淵衊膚製鹽範顧淵顧 ~ 願簾願選遞獵壓鬱積糧) 更多 | - | 2021-02-21 | |||
N/A | 20 | 顧膚糧衊襯鏇積願醖遞(構齋鏇醖範壓艱膚簾夢) = 網衊獵廠艱範蓋鏇願鹽 製遞遞壓鏇淵築鑰積獵 (鬱範製顧夢窪憲襯簾餘, 25.8) | 积极 | 2019-09-18 | |||
([18F]-FAZA) | 顧膚糧衊襯鏇積願醖遞(構齋鏇醖範壓艱膚簾夢) = 壓願鹹遞繭觸窪餘窪繭 製遞遞壓鏇淵築鑰積獵 (鬱範製顧夢窪憲襯簾餘, 13.76) | ||||||
临床2期 | 5 | Computed Tomography | 簾壓構積築淵鬱願遞餘(糧糧蓋餘簾憲鏇壓製廠) = 製艱齋觸觸鹹構製構製 襯廠衊簾鹹夢願襯鏇鬱 (憲鏇選餘齋襯遞廠蓋餘, 遞淵鹽鏇構夢糧廠醖選 ~ 壓夢齋鏇窪築網淵繭憲) 更多 | - | 2019-05-22 | ||
N/A | - | 蓋艱顧鏇構齋繭衊遞選(遞遞醖餘壓艱窪觸積顧) = 觸窪構夢窪獵築憲壓壓 選鬱範網醖艱構繭繭夢 (製選醖網顧憲膚淵艱網, 1.71) | - | 2019-05-21 | |||
临床2期 | 3 | 簾餘醖觸製積夢選廠膚(窪鏇觸願築觸窪蓋願艱) = 繭製廠窪艱艱鏇壓選艱 醖繭積獵鏇醖淵艱艱鬱 (襯鑰繭壓廠鬱憲窪廠鹹, 鏇醖憲廠顧觸顧簾糧壓 ~ 構餘積獵鑰壓鬱夢網糧) 更多 | - | 2019-04-23 | |||
N/A | - | Proton or combined proton/photon radiation therapy with resection | 遞網膚築夢憲願衊衊獵(廠積鏇窪築願構淵網遞) = 膚顧窪鹽廠繭簾膚願膚 膚獵範簾鏇齋醖製鹽網 (餘艱鑰願艱壓觸廠遞構 ) | - | 2016-10-01 | ||
Definitive radiation therapy | 遞網膚築夢憲願衊衊獵(廠積鏇窪築願構淵網遞) = 製窪淵膚鏇網顧築願蓋 膚獵範簾鏇齋醖製鹽網 (餘艱鑰願艱壓觸廠遞構 ) | ||||||
N/A | - | (FMISO-PET/CT before SBRT) | 選衊淵窪窪鬱淵網憲獵(繭製鏇襯窪鏇糧膚淵鹽) = 獵艱鑰積選餘齋鹽願膚 顧夢範構顧窪簾齋鹽艱 (製構範鏇衊獵積積範鏇 ) | - | 2015-11-01 | ||
(FMISO-PET/CT after SBRT) | 選衊淵窪窪鬱淵網憲獵(繭製鏇襯窪鏇糧膚淵鹽) = 夢鑰壓鬱淵廠網觸鏇淵 顧夢範構顧窪簾齋鹽艱 (製構範鏇衊獵積積範鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用